Trial Profile
A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tecemotide (Primary) ; Carboplatin; Cyclophosphamide; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.
- 03 Mar 2019 Planned End Date changed from 30 Jun 2023 to 22 May 2019.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer